Cargando…

Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists

[Image: see text] Purine (N)-methanocarba-5′-N-alkyluronamidoriboside A(3) adenosine receptor (A(3)AR) agonists lacking an exocyclic amine resulted from an unexpected reaction during a Sonogashira coupling and subsequent aminolysis. Because the initial C6-Me and C6-styryl derivatives had unexpectedl...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosh, Dilip K., Ciancetta, Antonella, Warnick, Eugene, O’Connor, Robert, Chen, Zhoumou, Gizewski, Elizabeth, Crane, Steven, Gao, Zhan-Guo, Auchampach, John A., Salvemini, Daniela, Jacobson, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970510/
https://www.ncbi.nlm.nih.gov/pubmed/26890707
http://dx.doi.org/10.1021/acs.jmedchem.5b01998
_version_ 1782445985425784832
author Tosh, Dilip K.
Ciancetta, Antonella
Warnick, Eugene
O’Connor, Robert
Chen, Zhoumou
Gizewski, Elizabeth
Crane, Steven
Gao, Zhan-Guo
Auchampach, John A.
Salvemini, Daniela
Jacobson, Kenneth A.
author_facet Tosh, Dilip K.
Ciancetta, Antonella
Warnick, Eugene
O’Connor, Robert
Chen, Zhoumou
Gizewski, Elizabeth
Crane, Steven
Gao, Zhan-Guo
Auchampach, John A.
Salvemini, Daniela
Jacobson, Kenneth A.
author_sort Tosh, Dilip K.
collection PubMed
description [Image: see text] Purine (N)-methanocarba-5′-N-alkyluronamidoriboside A(3) adenosine receptor (A(3)AR) agonists lacking an exocyclic amine resulted from an unexpected reaction during a Sonogashira coupling and subsequent aminolysis. Because the initial C6-Me and C6-styryl derivatives had unexpectedly high A(3)AR affinity, other rigid nucleoside analogues lacking an exocyclic amine were prepared. Of these, the C6-Me-(2-phenylethynyl) and C2-(5-chlorothienylethynyl) analogues were particularly potent, with human A(3)AR K(i) values of 6 and 42 nM, respectively. Additionally, the C2-(5-chlorothienyl)-6-H analogue was potent and selective at A(3)AR (MRS7220, K(i) 60 nM) and also completely reversed mouse sciatic nerve mechanoallodynia (in vivo, 3 μmol/kg, po). The lack of a C6 H-bond donor while maintaining A(3)AR affinity and efficacy could be rationalized by homology modeling and docking of these hypermodified nucleosides. The modeling suggests that a suitable combination of stabilizing features can partially compensate for the lack of an exocyclic amine, an otherwise important contributor to recognition in the A(3)AR binding site.
format Online
Article
Text
id pubmed-4970510
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-49705102017-02-18 Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists Tosh, Dilip K. Ciancetta, Antonella Warnick, Eugene O’Connor, Robert Chen, Zhoumou Gizewski, Elizabeth Crane, Steven Gao, Zhan-Guo Auchampach, John A. Salvemini, Daniela Jacobson, Kenneth A. J Med Chem [Image: see text] Purine (N)-methanocarba-5′-N-alkyluronamidoriboside A(3) adenosine receptor (A(3)AR) agonists lacking an exocyclic amine resulted from an unexpected reaction during a Sonogashira coupling and subsequent aminolysis. Because the initial C6-Me and C6-styryl derivatives had unexpectedly high A(3)AR affinity, other rigid nucleoside analogues lacking an exocyclic amine were prepared. Of these, the C6-Me-(2-phenylethynyl) and C2-(5-chlorothienylethynyl) analogues were particularly potent, with human A(3)AR K(i) values of 6 and 42 nM, respectively. Additionally, the C2-(5-chlorothienyl)-6-H analogue was potent and selective at A(3)AR (MRS7220, K(i) 60 nM) and also completely reversed mouse sciatic nerve mechanoallodynia (in vivo, 3 μmol/kg, po). The lack of a C6 H-bond donor while maintaining A(3)AR affinity and efficacy could be rationalized by homology modeling and docking of these hypermodified nucleosides. The modeling suggests that a suitable combination of stabilizing features can partially compensate for the lack of an exocyclic amine, an otherwise important contributor to recognition in the A(3)AR binding site. American Chemical Society 2016-02-18 2016-04-14 /pmc/articles/PMC4970510/ /pubmed/26890707 http://dx.doi.org/10.1021/acs.jmedchem.5b01998 Text en Copyright © 2016 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Tosh, Dilip K.
Ciancetta, Antonella
Warnick, Eugene
O’Connor, Robert
Chen, Zhoumou
Gizewski, Elizabeth
Crane, Steven
Gao, Zhan-Guo
Auchampach, John A.
Salvemini, Daniela
Jacobson, Kenneth A.
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
title Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
title_full Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
title_fullStr Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
title_full_unstemmed Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
title_short Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A(3) Adenosine Receptor Agonists
title_sort purine (n)-methanocarba nucleoside derivatives lacking an exocyclic amine as selective a(3) adenosine receptor agonists
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970510/
https://www.ncbi.nlm.nih.gov/pubmed/26890707
http://dx.doi.org/10.1021/acs.jmedchem.5b01998
work_keys_str_mv AT toshdilipk purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT ciancettaantonella purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT warnickeugene purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT oconnorrobert purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT chenzhoumou purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT gizewskielizabeth purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT cranesteven purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT gaozhanguo purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT auchampachjohna purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT salveminidaniela purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists
AT jacobsonkennetha purinenmethanocarbanucleosidederivativeslackinganexocyclicamineasselectivea3adenosinereceptoragonists